On October 30, 2019 Veracyte, Inc. (Nasdaq: VCYT) reported that new data advancing the understanding of genomic alterations – specifically, NTRK, RET, BRAF and ALK fusions – that are targeted by new precision medicine therapies for thyroid cancer will be presented at the 89th Annual Meeting of the American Thyroid Association, which will be held October 30-November 3, 2019 in Chicago (Press release, Veracyte, OCT 30, 2019, View Source [SID1234550046]). The findings will be presented in three posters and are derived from Afirma Xpression Atlas testing of Veracyte’s extensive biorepository of fine needle aspiration (FNA) samples from patients undergoing evaluation for thyroid cancer.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We believe our extensive collection of thyroid nodule FNA samples with RNA whole-transcriptome sequencing data uniquely enables us to broaden the scientific understanding of the role of key gene alterations in thyroid cancer," said Richard T. Kloos, M.D., senior medical director, endocrinology, at Veracyte. "Moreover, as the role of precision medicine in thyroid cancer treatment expands, our Afirma Xpression Atlas helps inform physicians’ treatment decisions for their patients with thyroid cancer using the same minimally invasive sample that is used for initial diagnosis with the Afirma Genomic Sequencing Classifier."
Following are details of the presentations, which will be presented in the Sheraton Grand Chicago Exhibit Hall:
Title:
Positive Predictive Value of NTRK, RET, BRAF and ALK Fusions in Bethesda III/IV Thyroid Fine-Needle Aspirates
Presenter:
Brendan C. Stack, M.D., University of Arkansas for Medical Sciences
Date/Time:
Friday, Nov. 1, 10:05 a.m.-11:00 a.m. and 12:15 p.m.-1:30 p.m. (Central Time)
Poster #:
Short Call Poster 55
Title:
Identification of Rare, Canonically Mutually Exclusive Variants in Thyroid FNAs
Presenter:
Bryan R. Haugen, M.D., University of Colorado School of Medicine
Date/Time:
Saturday, Nov. 2, 10:05 a.m.-11:00 a.m. and 11:45 a.m.-1:00 p.m. (Central Time)
Poster #
461
Title:
NTRK, RET, BRAF and ALK Fusions in Thyroid Fine-Needle Aspirates (FNAs)
Presenter:
Mimi I. Hu, M.D., University of Texas, M.D. Anderson Cancer Center
Date/Time:
Saturday, Nov. 2, 10:05 a.m.-11:00 a.m. and 11:45 a.m.-1:00 p.m. (Central Time)
Poster #
462